{"id":45867,"date":"2026-04-01T15:51:03","date_gmt":"2026-04-01T19:51:03","guid":{"rendered":"https:\/\/tvdelmarva.com\/wp\/fda-approves-eli-lillys-new-weight-loss-pill-to-compete-with-wegovy\/"},"modified":"2026-04-01T15:51:03","modified_gmt":"2026-04-01T19:51:03","slug":"fda-approves-eli-lillys-new-weight-loss-pill-to-compete-with-wegovy","status":"publish","type":"post","link":"https:\/\/tvdelmarva.com\/wp\/fda-approves-eli-lillys-new-weight-loss-pill-to-compete-with-wegovy\/","title":{"rendered":"FDA Approves Eli Lilly’s New Weight Loss Pill to Compete with Wegovy"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n

The Food and Drug Administration has granted approval to Eli Lilly’s new weight loss medication, introducing another pill option to a market currently led by injectable treatments and creating heightened rivalry with Novo Nordisk’s oral Wegovy product.<\/p>

The pharmaceutical giant’s new drug, orforglipron marketed under the brand name Foundayo, is taken once daily and works by copying the hunger-reducing GLP-1 hormone that’s also targeted by Lilly’s popular injection tirzepatide, which is marketed as Mounjaro for diabetes treatment and Zepbound for weight management.<\/p>

Financial analysts are weighing in with their perspectives on the new approval.<\/p>

Equisights Research analyst Parth Talsania noted the competitive advantages of the new medication. “Absence of dosing restrictions (for Foundayo) is a clear adherence lever and should support stronger conversion among new-to-therapy patients,” Talsania said. “For Novo, the risk is not immediate share loss but incremental pressure on patient starts and pricing as Lilly expands access points. Overall, in a nutshell, we believe Lilly’s early approval of orforglipron strengthens its competitive positioning in GLP-1s.”<\/p>

J.P. Morgan analyst Chris Schott expressed optimism about Lilly’s market position. “With this approval, we see the company (Lilly) well positioned with multiple potential sources of upside to numbers over the next several years,” Schott said. “We anticipate strong uptake of Foundayo… (but) expect inital Foundayo volumes to ramp more slowly relative to Oral Wegovy with a more significant inflection in 2H26\/2027+. As such, we expect a solid initial volume ramp, but one that may trend below that of Oral Wegovy.”<\/p>

Citi analyst Geoff Meacham highlighted the drug’s user-friendly features despite entering the market after its competitor. “Despite launching second behind Novo’s Wegovy pill, we think Foundayo’s superior ease-of-use more than offsets its 2.2% efficacy deficit and positions it to eventually capture the lion’s share of this rapidly expanding market. Crucially, the earlier-than-expected approval enables full participation in the upcoming broad Medicare access volume ramp,” Meacham said. “Clean safety label and crucially, no food restriction requirements that, altogether, underpin our 2026 $2.8 billion forecast.”<\/p>

UBS analyst Michael Yee acknowledged market uncertainties while remaining positive about Lilly’s prospects. “There is some debate on how LLY’s oral market share will play out given consensus for oral Wegovy has moved up from (about) $800 million earlier this year given a solid launch so far. But all this bodes well for LLY,” Yee said.<\/p>

Scotiabank analyst Louise Chen predicted international market success, stating: “We expect orforglipron to be more popular in most markets outside the U.S.”<\/p>

Cantor Fitzgerald analyst Carter Gould focused on competitive dynamics and market entry strategy. “While it’s unclear how broad commercial access will be ‘out of the gate’, or how it will ramp in those first few months, we see this as seizing some of the attention on the pricing front from Novo, and helping drive conversations and conversion,” Gould said.<\/p>","protected":false},"excerpt":{"rendered":"

The Food and Drug Administration has given the green light to Eli Lilly’s new daily weight loss pill called Foundayo. Wall Street analysts predict strong demand for the oral medication, which will compete directly with Novo Nordisk’s injectable and pill versions of Wegovy in the rapidly growing obesity treatment market.<\/p>\n","protected":false},"author":4,"featured_media":45866,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[837],"tags":[],"class_list":["post-45867","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1775073062365.jpg?fit=450%2C300&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/pbtNqq-bVN","jetpack-related-posts":[{"id":65606,"url":"https:\/\/tvdelmarva.com\/wp\/new-study-weight-loss-pill-helps-patients-keep-pounds-off-after-injectable-switch\/","url_meta":{"origin":45867,"position":0},"title":"New Study: Weight-Loss Pill Helps Patients Keep Pounds Off After Injectable Switch","author":"Admin","date":"May 12, 2026","format":false,"excerpt":"A new clinical trial shows patients who switched from weight-loss injections to Eli Lilly's oral medication Foundayo maintained most of their weight loss over a year. The study found those switching from Wegovy gained back only 2 pounds on average, while Zepbound users regained about 11 pounds.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778624685840.jpg?fit=450%2C253&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":45804,"url":"https:\/\/tvdelmarva.com\/wp\/new-daily-weight-loss-pill-gets-fast-track-fda-approval\/","url_meta":{"origin":45867,"position":1},"title":"New Daily Weight-Loss Pill Gets Fast-Track FDA Approval","author":"Admin","date":"April 1, 2026","format":false,"excerpt":"Federal health officials have given quick approval to Eli Lilly's new daily weight-loss pill called Foundayo. The medication helped patients lose an average of 25 pounds in clinical trials and will be available starting Monday with insurance copays as low as $25 monthly.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1775065090499.jpg?fit=1000%2C666&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1775065090499.jpg?fit=1000%2C666&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1775065090499.jpg?fit=1000%2C666&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1775065090499.jpg?fit=1000%2C666&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":63746,"url":"https:\/\/tvdelmarva.com\/wp\/eli-lillys-new-weight-loss-drug-shows-slower-start-than-competitor\/","url_meta":{"origin":45867,"position":2},"title":"Eli Lilly’s New Weight Loss Drug Shows Slower Start Than Competitor","author":"Admin","date":"May 8, 2026","format":false,"excerpt":"Eli Lilly's recently launched weight-loss medication Foundayo reached over 7,300 prescriptions in its fourth week on the market. The drug is facing competition from Novo Nordisk's Wegovy, which had a head start in the oral weight-loss medication market.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778246632928.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":47739,"url":"https:\/\/tvdelmarva.com\/wp\/weight-loss-pills-gain-popularity-over-injections-for-cost-and-convenience\/","url_meta":{"origin":45867,"position":3},"title":"Weight-Loss Pills Gain Popularity Over Injections for Cost and Convenience","author":"Admin","date":"April 6, 2026","format":false,"excerpt":"Medical professionals report growing demand for oral weight-loss medications as patients seek more affordable and convenient alternatives to injectable treatments. New pill options from major pharmaceutical companies are expanding access for those hesitant about needles.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1775472690333.jpg?fit=450%2C253&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":59106,"url":"https:\/\/tvdelmarva.com\/wp\/eli-lilly-shareholders-await-details-on-new-weight-loss-drug-performance\/","url_meta":{"origin":45867,"position":4},"title":"Eli Lilly Shareholders Await Details on New Weight-Loss Drug Performance","author":"Admin","date":"April 29, 2026","format":false,"excerpt":"Investors in pharmaceutical giant Eli Lilly are looking for early performance indicators of their new obesity medication Foundayo during Thursday's quarterly earnings report. The weight-loss pill launched in early April, competing directly with Novo Nordisk's oral Wegovy product.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1777458300983.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":69904,"url":"https:\/\/tvdelmarva.com\/wp\/affordable-weight-loss-pills-drawing-patients-away-from-compound-medications\/","url_meta":{"origin":45867,"position":5},"title":"Affordable Weight-Loss Pills Drawing Patients Away from Compound Medications","author":"Admin","date":"May 21, 2026","format":false,"excerpt":"New lower-priced weight-loss pill options from major pharmaceutical companies are encouraging patients to move away from compounded medications to FDA-approved branded treatments. Nine doctors across the country report seeing this shift as insurance coverage challenges continue to affect patient access.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779359032257.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/45867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/comments?post=45867"}],"version-history":[{"count":0,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/45867\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media\/45866"}],"wp:attachment":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media?parent=45867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/categories?post=45867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/tags?post=45867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}